Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma

By S. Willsie. 2010

915 citations recorded by the source corpus.

Subfields: Physiology, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/256147334b5453300d7015b9b078ba05da7e170f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

1. Sally E. Wenzel
2. Ian M. Adcock
3. P. Barnes

In Pulmonary and Respiratory Medicine

1. Sally E. Wenzel
2. P. Barnes

In Surgery

1. Sally E. Wenzel

Citations in the corpus

• International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma (2013, background): “These Th2 markers include exhaled nitric oxide (FeNO), which is widely available and serum periostin (currently available only for research and not applicable to children) and even blood eosinophils (online supplementary material 3, table S4 and Therapy Section for further details) [70, 187].”
• Eosinophils: changing perspectives in health and disease (2012, background): “Humanized IL-5-specific monoclonal antibodies (namely, mepolizumab and reslizumab) and a humanized IL-5Rα-specific monoclonal antibody (namely, benralizumab) are under exploration for the therapeutic management of dysregulated eosinophilia [92] [93] [94] [95] [96] 125 .”